Visterra-Serum Combine Forces For Dengue Therapy
This article was originally published in Scrip
US biotech, Visterra, has joined hands with vaccine giant, Serum Institute of India, to take its early stage monoclonal antibody product candidate (VIS513) for dengue forward.
You may also be interested in...
Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.